Seite auswählen

Several heavy weights in the pharmaceutical industry are interested in the Turkish pharmaceutical company Mustafa Nevzat. Among them is the Germany health group Fresenius, who, along with GlaxoSmithKline from the UK and Pfizer and Merck & Co from the USA, has joined the bidding competition for the object of acquisition estimated to be worth about 800 million dollars.

Mustafa Nevzat employs 1200 co-workers in Turkey and has, among other things, specialized in generic medications administered intravenously – similar to the Fresenius subsidiary Kabi.

[ilink url=] link to source (Handeslblatt)[/ilink]